Ditiocarb sodium

CAS No. 148-18-5

Ditiocarb sodium ( Sodium diethyldithiocarbamate )

Catalog No. M20541 CAS No. 148-18-5

Ditiocarb sodium (Sodium diethyldithiocarbamate) is an accelerator of the rate of copper cementation. Sodium diethyldithiocarbamate reduces the incidence of HIV infection.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 37 In Stock
1G 43 In Stock

Biological Information

  • Product Name
    Ditiocarb sodium
  • Note
    Research use only not for human use.
  • Brief Description
    Ditiocarb sodium (Sodium diethyldithiocarbamate) is an accelerator of the rate of copper cementation. Sodium diethyldithiocarbamate reduces the incidence of HIV infection.
  • Description
    Ditiocarb sodium (Sodium diethyldithiocarbamate) is an accelerator of the rate of copper cementation. Sodium diethyldithiocarbamate reduces the incidence of HIV infection.
  • Synonyms
    Sodium diethyldithiocarbamate
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    148-18-5
  • Formula Weight
    171.26
  • Molecular Formula
    C5H10NNaS2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:300 mg/mL (1751.72 mM)
  • SMILES
    [Na+].CCN(CC)C([S-])=S
  • Chemical Name
    Carbamodithioic acid diethyl- sodium salt

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.El-Saharty A A El-Hammamy N H El-Araby H A . Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation[J]. The Egyptian Journal of Aquatic Research 2015 41(4):289-293.
molnova catalog
related products
  • 4-Chloro-2-(trifluor...

    4-Chloro-2-(trifluoroacetyl)aniline hydrochloride is an inhibitor of HIV-1 RT (HIV reverse transcriptase) .

  • DRB

    DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 μM).

  • Dolutegravir

    Dolutegravir (GSK1349572) is a potent, next-generation HIV integrase (IN) inhibitor, inhibits HIV-1 integrase-catalyzed strand transfer with IC50 of 2.7 nM.